News Conference News ACC 2025 Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT Caitlin E. Cox March 29, 2025
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News ACC 2021 Low 1-Year Stroke Risk After Commercial Watchman Use Todd Neale May 15, 2021
News Conference News ACC 2021 Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III Todd Neale May 15, 2021
News Conference News ACC 2020 Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair L.A. McKeown April 07, 2020
News Conference News ACC 2020 Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients L.A. McKeown April 01, 2020
News Conference News ACC 2020 PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery Yael L. Maxwell March 31, 2020
News Conference News ACC 2020 A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI Todd Neale March 29, 2020
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
Presentation ACC 2018 Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants Presenter: Steve Deitelzweig March 12, 2018
News Conference News ACC 2017 Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE L.A. McKeown March 18, 2017
News Opinion Editor's Corner ACC 2016 Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016 Shelley Wood April 13, 2016
News Conference News ACC 2016 Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding Todd Neale April 06, 2016